GlaxoSmithKline JSC GlaxoSmithKlein Helsker RF

GlaxoSmithKline ("GlaxoSmithKlein") is a British pharmaceutical company that develops and manufactures medicines, vaccines and consumer health products. "GSK" formed in January 2001. Its headquarters are located in London.

For 2021, the company's main products are medicines for the treatment of asthma and COPD, products for HIV-infected people, as well as a wide range of vaccines. The company is actively engaged in research work in the field of immunoinflammatory diseases, neuroscience, metabolic pathways, ophthalmology, respiratory and viral diseases, as well as biopharmaceuticals. The consumer health products segment includes over-the-counter drugs, oral hygiene products and dietary supplements. The main brands are Aquafresh, Panadol, Nicorette, Tums and Sensodyne. The company has about 94 thousand employees.

Business in Russia

2023: Change of the general director of the Russian office of GSK - Yulia Strizhak became it

In mid-April 2023, the British pharmaceutical company GlaxoSmithKline (GSK) announced the change of the CEO of the Russian representative office. They appointed Julia Strizhak instead of Michael John Riley. Read more here.

2017

The central office of GSK Russia is located in Moscow. Also, GSK offices are open in St. Petersburg, Novosibirsk, Yekaterinburg, Irkutsk, Tomsk and Rostov-on-Don. The SmithKlein-Beecham Biomed vaccine plant is located in the Krasnogorsk district of the Moscow region. In Russia, GSK employs about 1000 people.

History

2023: $2 billion Bellus Health purchase

On April 18, 2023, GSK announced the purchase of Canadian biopharmaceutical company Bellus Health, which develops a drug for the treatment of refractory chronic cough, for $2 billion. Read more here.

2022

AstraZeneca through the court forbade the ex-leader to move to GSK

On September 1, 2022, it became known that AstraZeneca managed to stop the former top manager from moving to work for rival GSK after the High Court in London granted an injunction during a trial between the two largest pharmaceutical companies in the UK. Read more here.

$3.3 billion purchase of Affinivax biopharmaceutical company

On May 31, 2022, GSK announced that it was buying Boston-based biotech company Affinivax in a deal worth up to $3.3 billion. The deal comes as GSK seeks to strengthen its vaccine pipeline ahead of a planned split in its consumer healthcare business, Reuters said. Read more here.

GlaxoSmithKline bought Sierra Oncology for $1.9 billion

On April 13, 2022, GlaxoSmithKline (GSK) announced the purchase of biotechnology company Sierra Oncology for $1.9 billion as part of the British drugmaker's efforts to expand its line of drugs to fight cancer and prepare for the separation of its consumer health division. Read more here.

Haleon GSK Isolation Plan - as OTC

On February 22, 2022, GlaxoSmithKline plc announced the name of the company, which will hit the market in mid-2022 as a result of the separation of the over-the-counter drugs and consumer health products division into an independent business. She will conduct her activities under the Haleon brand. Read more here.

GSK sued Gilead $1.25 billion for stealing developments for HIV drug

On February 2, 2022, it became known that the British company GlaxoSmithKline (GSK) will receive $1.25 billion Gilead Sciences from as part of a settlement between its drug development unit HIV ViiV Healthcare and GSK. More. here

Unilever begins restructuring after GlaxoSmithKline deal breaks down

In mid-January 2022 Unilever , it announced it would focus on health and hygiene and sell off slow-growing brands as the company considers making a higher offer to buy the consumer division. GlaxoSmithKline The planned reorganization will be aimed at finding other ways to grow, and not at reducing costs. More. here

2016: 110,000 employees in 150 countries

In 2016, GSK operates in more than 150 countries around the world. 84 plants are located in 36 countries, including Russia. The largest research centers are open in the UK, USA, Belgium, Spain. The number of employees is about 110 thousand people, of which more than 13 thousand are employees of scientific laboratories.

2015: Turnover £23.92bn, net income £7.4bn

The company's turnover in 2015 amounted to about 23.92 billion pounds. Operating profit was around £5.72bn. Net profit - around £7.4bn.